摘要：历史经验表明，股市即将发生重大崩溃。Motley Fool咨询了三位投资者，他们推荐在股市崩溃前购入三大股票，作为更广泛的资本保全策略的一部分：强生、麦当劳和通用汽车。
If history is any guide, the stock market is due for a major crash soon. Nothing goes up forever, after all.
如果历史是任何指引,股市即将发生重大崩溃.毕竟，没有什么事情永远不会发生。
We thus asked three of our Motley Fool contributors which stocks they think are worth buying as part of a broader capital preservation strategy. Here's a look at why they picked Johnson & Johnson (NYSE: JNJ), McDonald's (NYSE: MCD), and General Motors (NYSE: GM).
因此，我们询问了我们的三个 Motley Fool 贡献者，他们认为哪些股票值得购买，作为更广泛的资本保全策略的一部分。下面是他们为什么选择强生（$强生(JNJ)$）、麦当劳（$麦当劳(MCD)$ ）和通用汽车（$通用汽车(GM)$）。
George Budwell (Johnson & Johnson): If there's any publicly traded company that knows how to weather a storm, it's healthcare giant Johnson & Johnson. Incorporated in 1887, J&J has gone on to build a bonanza of world-class brands, including Band-Aid, Benadryl, Listerine, Tylenol, among many, many others. And that's just the company's consumer healthcare segment. J&J also sports one of the most productive pharmaceutical pipelines in the world, as well as a top-notch medical device segment. The point is that J&J is an essential part of the global healthcare landscape, making it one of the absolute safest stocks you can own.
乔治·布德威尔（强生）：如果有一家上市公司知道如何应对风暴，那就是医疗保健巨头强生。J &强生（J&J）于1887年注册成立，并不断打造一大批世界级品牌，包括 Band-Aid 、 Benadryl 、 Listerine 、泰诺（Tylenol）等。这只是公司的消费者保健部门。强生（J&J）还拥有世界上最具生产力的制药管道之一，以及一流的医疗器械领域。问题在于，强生（J&J）是全球医疗保健领域不可或缺的一部分，使其成为你能拥有的绝对最安全的股票之一。
J&J has been going through a series of enormous challenges over the past few months, such as the scandal involving its baby powder and the loss of exclusivity for the top-selling arthritis medication Remicade. The stock, though, has still managed to shrug off these headwinds to gain a respectable 5.28% so far this year. Quite frankly, the market rarely turns a blind eye to these kinds of major risk factors, especially among blue-chip healthcare companies.
过去几个月，强生（J&J）一直在经历一系列巨大挑战，比如涉及婴儿爽身粉的丑闻，以及畅销关节炎药物 Remicade 的独家经营权的丧失。不过，该股今年迄今仍勉强摆脱了这些不利因素，上涨了5.28%。坦率地说，市场很少对这些主要风险因素视而不见，尤其是蓝筹医疗公司。
So, why does J&J get a pass? There are two likely reasons. First off, it has one of the best dividend programs among large-cap stocks. As proof, it's raised its dividend for 56 consecutive years, and its trailing payout ratio of 63% is among the lowest within all of big pharma. Secondly, J&J has repeatedly found ways to bounce back from patent expires, regulatory setbacks, and clinical miscues to deliver market-beating value for its shareholders. So, if you're searching for a stock to buy ahead of the next crash, this titan of the healthcare space should definitely be on your radar right now.
那么，为什么强生（J&J）公司获得了通行证？有两个可能的原因。首先，它在大型股中拥有最好的股息计划之一。作为证明，该公司已连续56年提高股息，其63%的派息率是所有大型制药公司中最低的。其次，强生（J&J）一再发现，要从专利到期、监管挫折和临床失误中恢复过来，为股东提供超越市场的价值。因此，如果你在下一次股市崩盘之前寻找一只股票来买入，那么这个医疗领域的巨头肯定会立刻成为你的雷达。 $强生(JNJ)$ #下周走势#
本文来自汇众医疗investank.com
精彩评论